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TNF-a has been implicated in the pathogenesis of, and the immune response against, HIV-1 infection. To clarify the roles of TNF-a against
HIV-1-related virus infection in an SHIV-macaque model, we genetically engineered an SHIV to express the TNF-a gene (SHIV-TNF) and
characterized the virus’s properties in vivo. After the acute viremic stage, the plasma viral loads declined earlier in the SHIV-TNF-inoculated
monkeys than in the parental SHIV (SHIV-NI)-inoculated monkeys. SHIV-TNF induced cell death in the lymph nodes without depletion of
circulating CD4+ T cells. SHIV-TNF provided some immunity in monkeys by increasing the production of the chemokine RANTES and by
inducing an antigen-specific proliferation of lymphocytes. The monkeys immunized with SHIV-TNF were partly protected against a pathogenic
SHIV (SHIV-C2/1) challenge. These findings suggest that TNF-a contributes to the induction of an effective immune response against HIV-1
rather than to the progression of disease at the early stage of infection.
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Cytokines mediate important immunoregulatory functions,
and changes in their relative levels play key roles in the
immune response against human immunodeficiency virus type-
1 (HIV-1) infection and the progression of HIV-1 infection to
clinical AIDS (Fauci, 1996; Matsuyama et al., 1991). Increased
levels of proinflammatory cytokines, especially tumor necrosis
factor alpha (TNF-a) and interleukin-6 (IL-6), were detected in
plasma and tissue of patient with AIDS (Fauci, 1993; Navikas
et al., 1995). TNF-a has been strongly implicated in the
progression of HIV-1 infection (Aukrust et al., 1994). A
possible mechanism for the progression of HIV-1 infection is
that TNF-a enhances HIV-1 replication (Folks et al., 1989; Poli
et al., 1990). Another possibility is that TNF-a induces0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.08.025
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E-mail address: a0d518u@cc.miyazaki-u.ac.jp (T. Haga).apoptosis of lymphocytes (Zheng et al., 1995), which destroys
T cells in the peripheral lymphoid systems (Badley et al., 1997;
Herbein et al., 1998).
On the other hand, TNF-a is also involved in controlling the
immune responses in some viral infections (Herbein and
O’Brien, 2000). Pretreatment of TNF-a inhibited replication
of the monocyte-tropic strain of HIV-1 (Herbein and Gordon,
1997). Thus, as a pleiotropic cytokine, TNF-a might contribute
not only to the pathogenesis of HIV-1 infection but also to the
immune response against HIV-1 infection. Despite the impor-
tance of TNF-a, little information is available on its role in the
pathogenesis of HIV-1 infection in vivo. The early events of
infection are especially unclear because it is difficult to monitor
humans immediately after they are infected.
Chimeric simian and human immunodeficiency virus
(SHIV) clones containing the HIV-1 tat, rev, vpu, and env
genes on a simian immunodeficiency virus (SIV) strain
mac239 background readily infected several susceptible
macaques. Inoculation of macaque monkeys with SHIV is an5) 151 – 161
www.e
Fig. 1. Genetic structures of SHIVs used in this study. (A) Parental SHIV-N
and SHIV-TNF. SHIV-NI has some unique restriction enzyme sites in place o
the nef gene of SHIV-NM3rN. SHIV-NM3rN was constructed from HIV-1
NL432 (dot regions) and SIV mac239 (white regions). In the SHIV-TNF, the
ClaI and XhoI region of the parental SHIV-NI was replaced by the human
TNF-a gene. The open reading frame including the initiation (ATG) and stop
(TGA) codons of the TNF-a gene is shown in the box. The flanking sequence
of the TNF-a initiation codon (ACCATGA) is an effective ribosomal initiation
sequence based on Kozak’s report (effective ribosomal initiation sequence
ANNATGN or GNNATGR). (B) Challenge virus SHIV-C2/1. SHIV-C2/1
(GenBank accession number AF217181) was generated by in vivo passage o
SHIV-89.6 through cynomolgus monkeys. SHIV-89.6 was constructed from
HIV-1 HXBc2, HIV-1 89.6, and SIV mac239.
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infection, for elucidating the etiology of AIDS, and for
evaluating the protective effects of vaccine candidates in vivo.
We previously reported the in vivo properties of one of the
SHIVs, SHIV-NM3rN (Kuwata et al., 1995). To assess the role
of cytokines in the pathogenesis of HIV-1-related virus
infection, the SHIV-nef vector having unique restriction
enzyme sites (designated as SHIV-NI) was constructed from
SHIV-NM3rN. Gene-deleted SHIVs can serve as vectors that
express cytokine genes in infected macaque monkeys (Enose
et al., 2004; Kozyrev et al., 2002). SHIV vectors containing a
cytokine gene appear to be appropriate tools for observing the
role of local production of a cytokine on virus replication,
pathogenesis, and immunogenicity, especially because the
inserted cytokine gene is expressed in the region where the
SHIV vector replicates.
To study the role of TNF-a against HIV-1-related virus
infection in an SHIV-macaque model, we constructed an SHIV
in which the nef gene is replaced with a human TNF-a coding
sequence (SHIV-TNF). In a previous in vitro study (Haga et al.,
2002), we showed that SHIV-TNF (i) expressed a significant
amount of biologically active TNF-a, (ii) replicated better than
the parental SHIV-NI in monkey peripheral blood mononuclear
cells (PBMCs), and (iii) induced a more severe cell death in
monkey PBMCs than did the parental SHIV-NI.
In this study, we demonstrate that inoculation of SHIV-TNF
in macaque monkeys induced cell death in peripheral lymph
nodes without a depletion of circulating CD4+ T cells. After the
acute viremic stage, the plasma viral load declined earlier in the
SHIV-TNF-inoculated monkeys than in the parental SHIV-NI-
inoculated monkeys. SHIV-TNF was found to produce some
immunity in macaque monkeys, leading to the elimination of
SHIV. Based on these results, we propose that TNF-a
contributes to the induction of an effective immune response
rather than to the progression of disease at the early stage of
HIV-1 infection.
Results
Virus load in rhesus macaques with SHIV-NI and SHIV-TNF
A recombinant SHIV was engineered to express TNF-a
(SHIV-TNF) in place of nef in SHIV-NI (Fig. 1A). To
investigate the in vivo properties of an SHIV-TNF, three
rhesus monkeys (MM343, MM350, and MM351) were
intravenously inoculated with 105 tissue culture 50% infectious
dose (TCID50) of SHIV-TNF, and two animals (MM346 and
MM349) were inoculated with 105 TCID50 of SHIV-NI as a
control. All monkeys were viremic within 2 weeks post-
inoculation (WPI) (Fig. 2A). This was also the case for two
monkeys (MM287 and MM288) that were inoculated with
same dose of SHIV-NI in a previous report (Enose et al., 2004).
The plasma viral RNA loads were about the same in all SHIV-
TNF- and SHIV-NI-inoculated monkeys, reaching a peak value
of 104 RNA copies/ml during 1 to 2 WPI. Up-regulation of the
plasma viral load in the SHIV-TNF-inoculated monkeys was
not more than that in the SHIV-NI-inoculated monkeys.I
f
:
fHowever, the kinetics of the viral loads was different between
the two groups. At the post-acute phase, the plasma viral loads
declined earlier in the SHIV-TNF group (becoming undetect-
able at about 4 WPI) than in the SHIV-NI group (becoming
undetectable at 6–8 WPI). After the acute viremic stage, the
plasma virus load declined to undetectable levels earlier in the
SHIV-TNF group than in the SHIV-NI group (P < 0.05 at 3
WPI).
Proviral DNAs in PBMCs from macaques infected with
SHIV-TNF were isolated, and the stability of the inserted TNF-
a gene in SHIV-TNF was studied by PCR with primer pairs
that recognized the site where the TNF-a gene had been
inserted. Due to the limited viral replication, proviral DNAs in
PBMCs of the SHIV-TNF inoculated monkeys were detected
up to 3 or 4 WPI. The full-length of the inserted TNF-a was
observed in the proviral DNAs (Fig. 2B).
Lymphocyte phenotyping of PBMC and lymph nodes
After the infection, the number of peripheral CD4+
lymphocytes remained within the normal level in both the
Fig. 2. Viral loads of SHIVs and TNF-a gene stability. (A) Viral RNA loads in plasma of monkeys inoculated with SHIV-TNF and SHIV-NI. Data for MM287 and
MM288 are from a previous report (Enose et al., 2004). Plasma viral RNA loads were measured by RT-PCR. The detection limit of this assay was 1.2  102 copies/
ml. (B) Stability of the inserted TNF-a gene in SHIV-TNF, as shown by PCR. DNA plasmids of SHIV-TNF (pSHIV-TNF DNA) and SHIV-NI (pSHIV-NI DNA)
were used as the templates of the control. MWM, molecular weight markers of 100-bp ladder.
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clinical changes were observed in any of the monkeys
during the observation period. These results showed that
SHIV-TNF did not cause an AIDS-like disease. No
significant differences were observed between the SHIV-
NI- and SHIV-TNF-inoculated monkeys in the cell surface
markers of PBMCs. In contrast, the percentage of CD20+ B
cells in the lymph nodes changed dramatically in the SHIV-
TNF-inoculated macaques after the inoculation of virus (Fig.
3B). After the inoculation of SHIV-TNF, development of
germinal centers in the lymph nodes was observed with
hematoxylin and eosin staining (data not shown). These data
suggest that the inoculation of SHIV-TNF induced the
activation of CD20+ B cells in the lymph nodes at the
early stage of the infection, without disturbing the immuno-
logical status.
Plasma levels of TNF-a and RANTES
We next examined the plasma levels of some cytokines by
enzyme-linked immunosorbent assay (ELISA). The levels of
TNF-a in the plasma of macaques infected with SHIV-TNF
and SHIV-NI were below the detection limit (15.6 pg/ml) of the
ELISA at all time points (data not shown).
TNF-a inhibited HIV-1 replication by inducing the
production of CC-chemokines such as regulated-on-activa-
tion-normal-T-cell-expressed-and-secreted (RANTES) (Lane
et al., 1999). To determine whether SHIV-TNF induces the
expression of RANTES, plasma levels of RANTES were
investigated (Fig. 3C). Interestingly, the plasma RANTES
levels in the SHIV-TNF-infected monkeys were higher
(about 3 times higher) than those in SHIV-NI-infected
monkeys at 2 WPI, when the plasma viral load was about
the same in the two groups. Plasma RANTES levels in the
parental SHIV-NM3rN-inoculated monkeys (Kwofie et al.,
2000) and two other SHIV-NI-inoculated monkeys (2.7 ng/
ml for MM287 and 2.0 ng/ml for MM288, respectively, at 2WPI) from our previous study were similar to those in the
SHIV-NI-infected monkeys. The difference of the plasma
RANTES levels between the SHIV-TNF-infected monkeys
and the SHIV-NI-infected monkeys is statistically significant
(P < 0.05 at 2 WPI). After 8 WPI, the plasma level of
RANTES declined to the pre-infection level in all SHIV-
TNF-infected monkeys.
Antibody titer
The humoral immune response was assessed with an HIV-1
particle agglutination assay. Induction of anti-HIV-1 antibodies
was first detected in two of three SHIV-TNF-infected monkeys
(MM343 and MM350) at 3 WPI (Fig. 3D). The antibody titers
for the other SHIV-TNF-inoculated monkey (MM351), SHIV-
NI-inoculated monkey, and the two SHIV-NI-infected monkeys
in our previous experiment (MM287 and MM288) (data not
shown) all slightly increased at 4 WPI. Although the data were
not statistically significant (P = 0.08 at 3 WPI), the results
showed that some SHIV-TNF-infected monkeys immediately
developed an antiviral antibody response during the early stage
of infection.
Induction of cell death in lymph nodes of SHIV-TNF-inoculated
monkeys
TNF-a induces apoptosis of lymphocytes (Zheng et al.,
1995). Spontaneous- or activation-induced ex vivo apoptosis of
lymphocytes was reported in infections of HIV-1-related
viruses (Gougeon et al., 1996; Iida et al., 2000; Reinberger et
al., 1999). Thus, we investigated the induction of cell death in
biopsy samples from lymph nodes by Annexin V assay and
terminal deoxynucleotidyl transferase dUTP nick end-labeling
(TUNEL) assay. In two of the SHIV-TNF-inoculated monkeys
(MM343 and MM351), the percentages of lymphocytes
undergoing cell death increased 24.2% and 17.5%, respective-
ly, at 2 WPI (Fig. 4A). In the SHIV-NI-inoculated monkeys
Fig. 3. Change in immune responses in rhesus monkeys after inoculation with SHIV-TNF (open symbols) and SHIV-NI (closed symbols). (A) CD4+ T lymphocyte
counts. Values were calculated from the percentage CD3+CD4+ cells measured by flow cytometry. The absolute number of lymphocytes was obtained by automated
blood cell counter. (B) Percentage of CD20+ B cells (CD3CD20+ cells) in the inguinal lymph nodes. Data were not obtained for all monkeys at each time. (C)
Plasma RANTES levels, as measured by ELISA. (D) Humoral immune responses, as expressed by anti-HIV-1 antibody titer. Antibody titer was analyzed by particle
agglutination assay and is expressed as the maximum dilution of plasma to give a positive result.
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lymphocytes after the virus inoculation remained at 4.1% and
7.5%, respectively, which were the pre-inoculation levels. The
percentage of Annexin-V-positive cells in the lymph nodes was
markedly higher in the SHIV-TNF-inoculated macaques than in
the SHIV-NI-inoculated macaques. Induction of cell death in
the SHIV-TNF group was also observed by the TUNEL assay
(Fig. 4B). These results show that induction of cell death in
inguinal lymph nodes in the SHIV-TNF group was significant-
ly higher than that in SHIV-NI group, suggesting that TNF-a
expressed by the SHIV-TNF-infected cells induced apoptosis in
lymph nodes in the virus-inoculated monkeys.
Induction of antigen-specific lymphocyte proliferative
responses in SHIV-TNF-inoculated macaques
To determine whether inoculation of the SHIV-TNF elicited
antigen-specific lymphocytes in the animals, proliferative
responses to SIV Gag were measured with PBMCs by uptake
of 5-bromo-2V-deoxyuridine (BrdU). During the experimental
period, antigen-specific T cell proliferation was inducedespecially in the SHIV-TNF-inoculated monkeys (Fig. 5A).
Proliferative responses to Gag in the SHIV-TNF group were
observed as early as 2 WPI. Subsets of proliferative lympho-
cytes were also characterized by combination of anti-BrdU and
surface marker staining. In the SHIV-TNF-inoculated monkeys,
the antigen-specific proliferative response was observed both in
CD4-positive and in CD8-positive cells (Fig. 5B). These results
show that antigen-specific T cell proliferation was induced
markedly in the SHIV-TNF group at the early stage of
infection.
The proliferative responses to a mitogen (Concanavalin A;
ConA) were low or absent in the SHIV-NI-inoculated monkeys
at 3 and 4 WPI, and then the response to ConA recovered to the
normal level afterward (Fig. 5C). In contrast, the SHIV-TNF-
infected macaques showed a continuous response to ConA.
Challenge with a pathogenic SHIV
To evaluate the protective effects provided by SHIV-TNF,
monkeys were challenged intravenously with 105 TCID50 of
heterologous pathogenic SHIV-C2/1 KS661 (Fig. 1B) at 8 WPI.
Fig. 4. Induction of cell death in inguinal lymph node mononuclear cells following infection with SHIV-TNF (open symbols) and SHIV-NI (closed symbols). Cells
were collected at the indicated times and incubated for 24 h before analyses. (A) Percentage of Annexin-V-positive cells. (B) Percentage of fragmentation of
chromosomal DNA, measured by flow cytometry with TUNEL assay. Data were not obtained for all monkeys at each time.
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and MM339) were infected intravenously with the same dose
(105 TCID50) of SHIV-C2/1 KS661. Circulating CD4
+
lymphocytes decreased in all of the control monkeys, reaching
less than 50 cells/Al in accordance with a previous report
(Shinohara et al., 1999) (Fig. 6A). The viral RNA in the plasma
of the control monkeys increased to above 107 copies/ml at 1
WPI and remained at a high level (Fig. 6B).
All of the monkeys in the SHIV-TNF group were more
resistant to the challenge than the control monkeys. The
circulating CD4+ T cell counts were maintained in all SHIV-
TNF-infected monkeys (Fig. 6A). The peak plasma virus loads
in the SHIV-TNF group (105 and 106 copies/ml) were two
orders of magnitude lower than those of the naive SHIV-C2/1
KS661-inoculated monkeys (Fig. 6B). Interestingly, the plasma
virus loads in two of the three SHIV-TNF-inoculated monkeys
(MM343 and MM351) rapidly declined to below the detection
limit at 4 weeks post-challenge (WPC). The peak plasma viral
load of one of the SHIV-NI-infected monkeys (MM349; 107
copies/ml) was similar to that of the control monkeys. The
circulating CD4+ T cell count in MM349, an SHIV-NI-infected
monkey, remained within the normal range in spite of a
transient but intense viremia in the plasma (Fig. 6A). These
results show that all SHIV-TNF-inoculated monkeys were
partially protected from challenge, with a pathogenic SHIV
having a heterologous HIV-1 Env. Moreover, some SHIV-
TNF-infected monkeys may have immediately eliminated the
heterologous challenge virus in the plasma.
Discussion
The aim of this study was to clarify the role of TNF-a
against HIV-1-related virus infection in an SHIV-macaque
model. For this purpose, we have genetically engineered an
SHIV to express the TNF-a gene so that, when viral
transcription occurs, TNF-a will also be produced locally.We compared the in vivo properties of macaques infected with
SHIV-TNF with those of its parental SHIV-NI. Although the
number of animals examined was small, some virologic and
immunologic parameters in macaques infected with SHIV-TNF
and with SHIV-NI were different between the groups.
In a previous in vitro study, SHIV-TNF was found to
replicate better than SHIV-NI does in macaque PBMCs (Haga
et al., 2002). In vivo, however, the plasma viral loads were
about the same in the two groups during acute infection. The
plasma viral loads in the SHIV-TNF-inoculated monkeys
dramatically declined to undetectable levels after the acute
phase of the infection, while the viral loads of the parental
SHIV-NI-inoculated monkey declined gradually. The spread of
the virus was suppressed in the animals infected with SHIV-
TNF. Suppression of the virus may have been due to cell deaths
in the lymph nodes from the SHIV-TNF-inoculated monkeys.
An efficient induction of cell death, through the TNF/TNF-
receptor (TNFR) pathway, could restrict virus replication by
eliminating virus-infected cells (Herbein and O’Brien, 2000).
HIV-1-infected lymphocytes treated with TNF-a underwent
apoptosis resulting in a decreased HIV-1 replication, suggest-
ing that cell death helps to inhibit the spread of HIV-1 (Lazdins
et al., 1997). Insertion of the TNF-a gene in the SHIV induced
a rapid cell death at the site where virus replicates, with a
subsequent reduction of the spread of the virus.
A cytokine-expressing SIV was observed to lose the
cytokine gene within several weeks in vivo (Gundlach et al.,
1997). In our study, the proviral DNA isolated from PBMCs of
macaques inoculated with SHIV-TNF during the viremia
retained full-length TNF-a inserts. Due to the limited and
local nature of viral replication, we could not detect TNF-a in
the plasma of animals inoculated with SHIV-TNF. However,
the TNF-a gene inserted in SHIV-TNF was stable in vivo
during the viremia.
In vitro studies have suggested that pretreatment of
macrophages with TNF-a helps to protect them against HIV-
Fig. 5. T cell proliferation in SHIV-TNF- and SHIV-NI-inoculated rhesus monkeys in response to an SHIV-specific antigen (SIV Gag; A and C) or a mitogen
(ConA; B). (A, B) Lymphocytes proliferation, as measured by BrdU uptake, in response to SIV Gag (A) and ConA (B). Data are expressed as the mean of
triplicate determinations T SEM. (C) Percentage of the SIV Gag-specific proliferated cells (solid bars) and unstimulated cells (open bars) at 6 WPI that were
CD4+ or CD8+ cells, as measured by flow cytometry.
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chemokines such as macrophage inflammatory protein-1 alpha
(MIP-1a), beta (MIP-1h), and RANTES (Herbein and Gordon,
1997; Lane et al., 1999). In this experiment, an increase in
RANTES production was observed in the SHIV-TNF-inocu-
lated monkeys. At the peak, the plasma level of RANTES was
three times higher in the SHIV-TNF-infected monkeys than in
the SHIV-NI-infected monkeys. RANTES is known to
suppress a CC-chemokine receptor 5 (R5)-tropic HIV-1 in
vitro (Alkhatib et al., 1996; Cocchi et al., 1995), but not a
CXCR4 (X4)-tropic virus including HIV-1 NL432, the sourceof the env gene of SHIV-TNF. Therefore, the high RANTES
production probably did not limit the replication of SHIV-TNF
in this study. Many cohort studies have suggested that an
increase of RANTES inhibits the development of AIDS
(Aukrust et al., 1998; Garzino-Demo et al., 1999). Further-
more, RANTES regulates cell migration to the site of
inflammation. The appropriate expression of RANTES can
improve the host immune response against HIV-1. Together,
our result suggests that TNF-a helps to induce an effective
immune response against HIV-1 by mediating the expression of
the CC-chemokine RANTES.
Fig. 6. Change in the number of circulating CD4+ T cells (A) and SHIV-C2/1-specific viral RNA loads (B) of the SHIV-NI- and SHIV-TNF-inoculated monkeys after
SHIV-C2/1 challenge. Values are expressed as a percentage of the pre-challenge values of each monkey. Plasma viral RNA loads after the heterologous pathogenic
SHIV (SHIV-C2/1) challenge were measured by RT-PCR. The detection limit of this assay was 1.2  102 copies/ml. Left panels show results for naive SHIV-C2/1-
inoculated monkeys (MM338, MM339, MM298, and MM299).
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of SHIV-TNF induced a remarkable antigen-specific T cell
proliferation at the early stage of infection. In human, TNF-a
enhances mitogen- and antigen-induced T cell proliferation
(Tartaglia et al., 1993; Yokota et al., 1988). TNF-a produced
by HIV-1-infected macrophages has been reported to stimulate
bystander T cell proliferation (Godard and Chermann, 1998).
Our results suggest that the co-expression of viral antigen and
TNF-a stimulates antigen-specific T cell proliferation. Anti-
gen-specific T cell proliferation is important for the control of
AIDS pathogenesis. Proliferation of HIV-1 p24-specific CD4+
T cells, which has been associated with control of acute
infection and delayed disease progression, has been shown to
inhibit the replication of HIV-1 (Rosenberg et al., 1997).
Therefore, TNF-a appears to induce effective antigen-specific
immune responses of lymphocytes, which may help to prevent
the progression of disease.
The proliferative responses to a mitogen (ConA) were low
or absent in parental SHIV-NI-inoculated monkeys during the
period from 3 WPI to 4 WPI. Mitogen-stimulated proliferation
of lymphocytes was also found to be inhibited during the acute
stage of HIV-1 infection (Cooper et al., 1988; Pedersen et al.,
1990). A transient impairment of proliferative response tomitogens has been correlated with host immune suppression. A
decrease in the level of TNF-a in a virus infection was found to
suppress mitogen- and antigen-stimulated lymphocyte prolif-
eration (Griffin et al., 1994), and mitogen- and antigen-
stimulated lymphocyte proliferation was restored by addition
of exogenous TNF-a (Kasahara et al., 2003). In the present
study, the SHIV-TNF-infected macaques showed a continuous
proliferative response to ConA during the observation period.
These results suggest that co-expression of TNF-a by a
genetically engineered virus sustains the virus-induced immune
suppression.
Most studies of the relationship between TNF-a and HIV-1
infection have focused on patients at the AIDS stage. TNF-a
has been implicated in the progression of AIDS because of
the possibilities that TNF-a enhances HIV-1 replication
(Folks et al., 1989; Poli et al., 1990) and induces apoptosis
of lymphocytes (Badley et al., 1997; Herbein et al., 1998). In
this study, SHIV-TNF replicated transiently in inoculated
monkeys, and the number of peripheral CD4+ lymphocytes
remained within the normal level in all SHIV-TNF-inoculated
monkeys, despite the induction of cell death in inguinal
lymph nodes. Although we cannot exclude the possibility that
TNF-a contributes to disease progression in the late stage of
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develop AIDS-like disease during the experimental period.
At the early stage of HIV-1 infection, expression of TNF-a
also increased in some individuals (von Sydow et al., 1991),
which was considered to contribute to the inflammatory
response seen in acute HIV-1 infection. The present results
demonstrate that SHIV-TNF induced the expression of
RANTES, antigen-specific T cell proliferation, and rapid cell
death with a subsequent reduction of plasma viral loads at the
early stage of infection. The appearance of TNF-a activates the
virus-specific immune response, which contributes to viral
clearance. Therefore, at the early stage of HIV-1 infection, we
propose that TNF-a plays a role in the induction of an effective
immune response, rather than in the progression of the disease.
The immune responses induced by an attenuated virus can
increase the immunity to a pathogenic virus. We previously
reported that macaque monkeys immunized with the parental
SHIV-NI were partially protected from a challenge with a
heterologous pathogenic SHIV (Enose et al., 2002; Ui et al.,
1999). In the present study, the monkeys that received the
inoculation of SHIV-TNF were partially protected from a
challenge with a heterologous pathogenic SHIV-C2/1. The
immune response induced by the inoculation of SHIV-TNF
helped to suppress the spread of a heterologous pathogenic
SHIV. It is noteworthy that the challenge virus load rapidly
declined to below the detection limit in some SHIV-TNF-
inoculated monkeys.
In general, the immunogenicity of live-attenuated vaccines
tends to increase with increasing virulence (Johnson and
Desrosiers, 1998). Therefore, in attenuating a live virus, there
is a trade-off between safety and immunogenicity. A good way
to overcome this problem is to genetically engineer a virus to
co-express an anti-viral agent such as a cytokine adjuvant. The
expression of an inserted cytokine gene from a genetically
engineered vaccine virus provides adjuvant effects locally at the
site of virus replication. Several studies have demonstrated that
insertion of a cytokine in a gene-deleted live-attenuated SIVs
could boost the immunogenicity of the viruses and enhance its
protection ability (Giavedoni et al., 1997; Stahl-Hennig et al.,
2003). For the immune adjuvant effect of TNF-a, a combination
of cytokines including TNF-a enhanced cellular immune
responses resulting in a more effective immune-modulating
effect against HIV-1 in the rodent model (Ahlers et al., 1997,
2003). In this study, SHIV-TNF induced antiviral immune
responses in the virus-inoculated monkeys that subsequently
rapidly cleared the virus. The rapid viral clearance and
enhanced immunogenicity may improve the safety of a live-
attenuated virus vaccine candidate because these responses will
reduce the risks of residual pathogenicity, reversion to a
pathogenic virus, and recombination of the vaccine virus with
the challenge virus (Baba et al., 1999; Gundlach et al., 2000).
These results raise the possibility that a genetically engineered
anti-viral agent, such as TNF-a, can improve the safety and
immunogenicity of an attenuated live virus vaccine.
In conclusion, we showed that SHIV-TNF induces (i) rapid
clearance of virus after the acute viremic stage, (ii) cell death in
peripheral lymph nodes without depletion of circulating CD4+T cells, (iii) up-regulation of the plasma level of the chemokine
RANTES, (iv) antigen-specific proliferation of lymphocytes,
and (v) protection against a pathogenic SHIV-C2/1 challenge.
These findings suggest that TNF-a contributes to the induction
of an effective immune response at the early stage of HIV-1
infection and that a genetically engineered virus to co-express
the TNF-a gene can be useful for studying the immune-
modulating effect of TNF-a in HIV-1-related infections.
Materials and methods
Viruses and animals
SHIV-NI and SHIV-TNF were constructed from SHIV-
NM3rN as previously described (Fig. 1A) (Haga et al., 2002).
A heterologous pathogenic SHIV-C2/1 KS661 was used for the
challenge virus (Fig. 1B). SHIV-C2/1 KS661 is a molecular
clone derived from SHIV-C2/1 and causes rapid CD4+ T cell
depletion (GenBank accession number AF217181) (Shinohara
et al., 1999). The env gene of SHIV-C2/1 was derived from
HIV-1 89.6 and is antigenically different from the env gene of
SHIV-NI and SHIV-TNF. Virus stocks were prepared with the
CD4+ human T cell line M8166 (a subclone of C8166) as
described elsewhere (Haga et al., 2002). Five female rhesus
monkeys (Macaca mulatta) were maintained in accordance
with regulations approved by the Institutional Animal Care and
Use Committee of the Institute for Virus Research, Kyoto
University, and were housed in single cages within a biosafety
level 3 facility. Blood samples were collected under anesthesia
with ketamine hydrochloride.
Inoculation of rhesus monkeys with SHIV and sample
collection
To investigate the in vivo properties of SHIV-TNF and
SHIV-NI, three rhesus monkeys (MM343, MM350, and
MM351) were inoculated intravenously with 105 TCID50 of
SHIV-TNF, and two monkeys (MM346 and MM349) were
inoculated with 105 TCID50 of SHIV-NI. Blood samples were
phenotypically characterized on a FACScan flow cytometer
(Becton Dickinson, San Jose, CA) and were separated into
plasma and PBMCs with lymphocyte separation solution
(Nacalai Tesque, Inc. Kyoto, Japan). Inguinal lymph nodes
were obtained from these animals by biopsy at 2 and 4 WPI
and before infection. Single-cell suspensions were prepared
from the inguinal lymph nodes with a 100 Am nylon cell
strainer (Becton Dickinson). Part of the inguinal lymph nodes
was fixed in 4% paraformaldehyde and embedded in paraffin
for histopathologic analysis. To evaluate the protective effects
provided by the SHIV-TNF or SHIV-NI inoculation, all
monkeys were challenged intravenously with 105 TCID50 of
SHIV-C2/1 KS661 at 8 WPI.
Plasma viral RNA loads
Plasma viral RNA loads were determined by quantitative
RT-PCR (Enose et al., 2002; Suryanarayana et al., 1998). The
Y. Shimizu et al. / Virology 343 (2005) 151–161 159plasma viral loads of SHIV-NI, SHIV-TNF, and the challenge
virus were differentially evaluated with primer pairs specific to
SHIV-NM3rN and SHIV-C2/1, respectively (Enose et al.,
2004). These reactions were performed with a Prism 7700
Sequence Detector (Applied Biosystems, Foster City, CA) and
analyzed using the manufacturer’s software. The viral RNA in
the plasma samples was quantified based on the copy number
of the standard samples.
Isolation of proviral DNA
Proviral DNA was extracted from 1  106 PBMCs and
amplified by PCR with primers specific for the nef region.
Cellular DNAs were extracted from PBMCs of the inoculated
monkeys using DNeasy tissue kits (QIAGEN, Hilden,
Germany) according to the manufacturer’s recommendations.
The proviral DNA fragments covering the inserted TNF-a
gene in SHIV-TNF were amplified from each cellular DNA
by PCR as previously described (Haga et al., 2000). The
lengths of DNA fragments generated by this reaction were
847 bp for the SHIV containing the intact TNF-a gene and
154 bp for SHIV-NI.
Determination of TNF-a and RANTES
Plasma samples were thawed and centrifuged at 10,000  g
for 10 min at 4 -C. TNF-a levels in the plasma were determined
by ELISA using a Quantikine Human TNF-a ELISA kit (R&D
Systems, Inc., Minneapolis, MN) and a Monkey TNF-a ELISA
kit (Biosource International, Inc., Camarillo, CA). Plasma
RANTES concentration was measured using a human
RANTES ELISA kit (R&D Systems), which is known to
cross-react with rhesus RANTES (Kwofie et al., 2000).
Lymphocyte analysis
Blood samples and inguinal lymph node suspensions were
stained with combinations of the following monoclonal
antibodies (MAbs): anti-human CD4 (NU-TH/I, Nichirei,
Tokyo, Japan), anti-human CD8 (Leu-2a, Becton Dickinson),
anti-monkey CD3 (FN18, Biosource International), anti-human
CD20 (Leu-16, Becton Dickinson), anti-human CD29 (4B4;
Beckman Coulter, Miami, FL), anti-human CD14 (RMO52;
Beckman Coulter), anti-human CCR5 (3A9; Pharmingen, San
Diego, CA), anti-human CXCR4 (12G5; Pharmingen), and
anti-Ki67 antigen (Ki-67, DAKO, Glostrup, Denmark). Ten
thousand events per sample were acquired by a FACScan flow
cytometer, and data were analyzed by CellQuest software
(Becton Dickinson) and FlowJo software (TreeStar, San Carlos,
CA). Absolute lymphocyte counts in the blood were deter-
mined with an automated blood cell counter (F-820; Sysmex,
Kobe, Japan).
Analysis of cell death
The percentages of lymphocytes undergoing cell death
were determined by Annexin V assay and TUNEL assay.Mononuclear cells (1  106) from the blood and lymph
nodes were cultured for 24 h ex vivo in 24-well culture
plates in complete RPMI medium (RPMI 1640 with 10%
heat-inactivated fetal calf serum) per milliliter at 37 -C. In
the Annexin V assay, a MEBCYTO apoptosis kit (MBL,
Nagoya, Japan) was used according to the manufacturer’s
instructions. As another assay of cell death, fragmentation of
chromosomal DNA was detected with a TUNEL assay. An
APO-BrdU kit (Pharmingen) was used according to the
manufacturer’s instructions. The cells were then analyzed by
flow cytometry.
Proliferation assays
Lymphocyte proliferation was measured by incorporation of
BrdU into the stimulated lymphocytes. PBMCs (2  105) were
cultured in a 96-well plate in complete RPMI medium. The
recombinant viral proteins of SIV Gag (SIVmac251 p27; 5.0
Ag/ml; Advanced Biotechnologies, Inc., Columbia, MD) were
used for antigen-specific stimulation. Concanavalin A (ConA;
0.5 Ag/ml; Sigma, St. Louis, MO) was used for polyclonal
stimulation. The plates were incubated for 72 h at 37 -C.
After the incubation, the cells were cultured for another 24
h in the presence of BrdU. Then, lymphocyte proliferation
was measured using a cell proliferation ELISA kit (Roche
Diagnostics, Basel, Switzerland) and a BrdU-Flow kit
(Pharmingen) following the manufacturer’s recommendations.
In the ELISA, the absorbance of the incorporated BrdU was
measured by a microplate reader at 450 nm. The experiment
was performed in triplicate. In another cell proliferation assay,
to characterize the lymphocyte subsets in the proliferated
cells, cells were stained for surface markers with MAb CD4-
PE (Nichirei) and CD8-PerCP (Becton Dickinson). The cells
were stained with MAb BrdU-FITC after fixation and
permeabilization and then analyzed by flow cytometry.
Proliferation responses to the antigens were considered
positive if the stimulation index (SI = titers for antigen-
stimulated wells / titers for control wells without antigens)
exceeded 2.0 (Ahmed et al., 2002).
Determination of anti-SHIV antibody titers
Anti-SHIV antibody titers in the plasma of the monkeys
were determined using a commercial particle agglutination
test kit (Genedia HIV-1/2, Fujirebio Inc., Tokyo, Japan). The
samples were serially two-fold diluted and assayed follow-
ing the manufacturer’s recommendations. The end-point titer
was determined as the highest dilution to give a positive
result.
Statistical analysis
Differences between the groups of plasma viral RNA loads,
plasma RANTES level, and anti-SHIV antibody titers in the
plasma were compared by statistical analysis using the Mann–
Whitney U test; P values <0.05 were considered statistically
significant.
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